Literature DB >> 1979724

Dystrophin analysis in Duchenne and Becker muscular dystrophy carriers: correlation with intracellular calcium and albumin.

L Morandi1, M Mora, E Gussoni, S Tedeschi, F Cornelio.   

Abstract

Immunocytochemical localization and immunoblot analysis of dystrophin in muscle fibers of 11 obligate and probable, and 7 possible carriers of Duchenne and Becker muscular dystrophy revealed an abnormal expression of the protein in 3 of them. Localization of calcium and albumin, as endogenous markers of extracellular fluid penetration, showed the presence of both molecules inside some fibers lacking dystrophin. Our morphological studies show that the initial stages leading to fiber necrosis in Duchenne muscular dystrophy are present in carriers with mosaicism. Comparison of dystrophin studies with restriction fragment length polymorphism analysis and creatine kinase levels showed that neither immunocytochemical nor immunoblot techniques for dystrophin are sensitive enough to provide a basis for genetic counseling.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979724     DOI: 10.1002/ana.410280512

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  9 in total

1.  Dystrophin immunohistochemistry in a symptomatic carrier of Becker muscular dystrophy.

Authors:  K Haginoya; K Yamamoto; K Iinuma; T Yanagisawa; Y Ichinohasama; M Shimmoto; Y Suzuki; K Tada
Journal:  J Neurol       Date:  1991-10       Impact factor: 4.849

2.  Somatic mosaicism for a deletion of the dystrophin gene in a carrier of Becker muscular dystrophy.

Authors:  T Voit; E Neuen-Jacob; V Mahler; A Jauch; M Cremer
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

3.  Congenital muscular dystrophy. A study on the variability of morphological changes and dystrophin distribution in muscle biopsies.

Authors:  Q H Leyten; H J ter Laak; F J Gabreëls; W O Renier; K Renkawek; R C Sengers
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

4.  Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis.

Authors:  L V Nicholson; M A Johnson; K M Bushby; D Gardner-Medwin; A Curtis; I B Ginjaar; J T den Dunnen; J L Welch; T J Butler; E Bakker
Journal:  J Med Genet       Date:  1993-09       Impact factor: 6.318

5.  Investigation of a female manifesting Becker muscular dystrophy.

Authors:  I A Glass; L V Nicholson; E Watkiss; M A Johnson; R G Roberts; S Abbs; S Brittain-Jones; H G Boddie
Journal:  J Med Genet       Date:  1992-08       Impact factor: 6.318

6.  Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine.

Authors:  P Bernasconi; E Torchiana; P Confalonieri; R Brugnoni; R Barresi; M Mora; F Cornelio; L Morandi; R Mantegazza
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

7.  Dystrophin abnormalities in Duchenne and Becker dystrophy carriers: correlation with cytoskeletal proteins and myosins.

Authors:  M Mora; L Morandi; A Piccinelli; E Gussoni; M Gebbia; F Blasevich; F Dworzak; F Cornelio
Journal:  J Neurol       Date:  1993-09       Impact factor: 4.849

8.  Direct visualization of the dystrophin network on skeletal muscle fiber membrane.

Authors:  V Straub; R E Bittner; J J Léger; T Voit
Journal:  J Cell Biol       Date:  1992-12       Impact factor: 10.539

9.  Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy.

Authors:  Thomas C Roberts; K Emelie M Blomberg; Graham McClorey; Samir El Andaloussi; Caroline Godfrey; Corinne Betts; Thibault Coursindel; Michael J Gait; C I Edvard Smith; Matthew J A Wood
Journal:  Mol Ther Nucleic Acids       Date:  2012-08-14       Impact factor: 10.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.